TEL AVIV, Israel, June 19, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1
Growth Capitalist (https://growthcapitalist.com/2018/06/galmed-pharmaceuticals-ltd-announces-pricing-of-public-offering-of-ordinary-shares/)
TEL AVIV, Israel, June 19, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1